Stocks Health care ABVX
NASDAQ · Health careAbivax S.A. (ABVX)
It posted a net loss of €336.1M. In fiscal 2025 capital spending exceeded operating cash flow by €161.3M. At December 31, 2025 it held €516.7M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 23, 2026.
Watch ABVX in 60 secondsWhat Abivax S.A. does
Abivax S.A. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ABVX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -€336.1M | -€4.83 | -€161.3M |
| 2024 | n/a | -€176.2M | -€2.80 | -€154.7M |
| 2023 | n/a | -€147.7M | -€3.43 | -€97.4M |
| 2023 | n/a | -€60.7M | -€3.18 | -€54.2M |
| 2021 | n/a | -€42.5M | -€2.75 | -€45.1M |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Abivax S.A. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 21, 2026Form F-6EF filing F-6EF
- September 21, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- July 6, 2026Activist stake changed SCHEDULE 13D/A
- July 2, 2026
- July 2, 2026
- July 1, 2026
- June 30, 2026
- June 30, 2026
Insider trades
What the people running Abivax S.A. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns ABVX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Sofinnova Crossover I SLP ("SC")13D, may seek influence with 6 related filers | 8% | October 30, 2023 |
| Chen Yu13G, passive with 4 related filers | 7% | August 14, 2026 |
| Raymond Debbane13G, passive with 7 related filers | 6% | August 13, 2026 |
Largest institutional holders
Insiders
Questions about ABVX
What does Abivax S.A. do?
Abivax S.A. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ABVX.
Is Abivax S.A. profitable?
No. In fiscal 2025 it reported a net loss of €336.1M.
When did Abivax S.A. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 23, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the form F-6EF filing from September 21, 2026.
Similar companies
Compare ABVX with
Follow ABVX
Get an email when Abivax S.A. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ABVX: get an email when it filesWhere the numbers come from
Financial figures are the values Abivax S.A. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.